Product Description
an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT03099109)
Mechanisms of Action: TIM3 Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-194672 | P1 |
Unknown |
Oncology Solid Tumor Unspecified |
2020-01-10 |
|
| I9A-MC-JLDA | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2019-12-10 |
28% |